Please login to the form below

Not currently logged in
Email:
Password:

M7824

This page shows the latest M7824 news and features for those working in and with pharma, biotech and healthcare.

Immuno-oncology at ASCO: survival data, combinations and new indications

Immuno-oncology at ASCO: survival data, combinations and new indications

Also on the agenda are preliminary clinical results with M7824, an investigational TGF‑ beta trap/anti-PD-L1 bi-functional immunotherapy fusion protein in human papillomavirus (HPV)-associated cancers and

Latest news

  • Merck takes novel immuno-oncology drug into clinical trials Merck takes novel immuno-oncology drug into clinical trials

    The bifunctional immunotherapy - called M7824 - was one of the highlights of an R&D update held yesterday at which the company highlighted its pipeline of new drug candidates in its three ... rate. Merck is not ready to divulge the molecular targets for

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics